NeutroSpec Promos Tout Broad, Unsupported Indications, FDA Chides
This article was originally published in The Pink Sheet Daily
Executive Summary
The withdrawn imaging agent is cited for violations made during the 2005 American Pharmaceutical Association annual meeting.
You may also be interested in...
NeutroSpec Pulled From The Market
FDA "reconsidered" the risk/benefit balance for Mallinckrodt/Palatin Technologies' appendicitis imaging agent, which has been associated with cardiopulmonary events.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.